Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data

Danese, Mark D.; Reyes, Carolina; Gleeson, Michelle; Halperin, Marc; Skettino, Sandra; Mıkhael, Joseph

doi:10.1097/mlr.0000000000000486

Cited by 24 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, hospitalization in Italy costs around € 800/day (excluding therapeutic interventions) [75]. These considerations closely match those with other experiences in immunology [75,76] and hematology [77].…”

Section: Rituximab (Rtx)supporting

confidence: 75%

Treatment of primary membranous nephropathy: where are we now?

et al. 2017

View full text Add to dashboard Cite

In the last 10 years, basic science and clinical research have made important contributions to the understanding and management of primary membranous nephropathy (MN). The identification of antibodies directed against the M-type phospholipase A receptor (PLA2R) and thrombospondin type-1 domain-containing 7A protein have added a new perspective on diagnosis, monitoring the immunological activity, predicting prognosis and guiding therapy in patients with primary MN. Mounting evidence suggests that quantification and follow-up of antiPLA2R Abs levels can help in assessing prognosis and evaluate the response to treatment. The kidney disease improving global outcomes guidelines published in 2012 have not been updated. New data on the use of rituximab suggest it should be considered as a potential initial therapy in the treatment of patients with primary MN.

show abstract

Section: Rituximab (Rtx)supporting

confidence: 75%

Treatment of primary membranous nephropathy: where are we now?

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Real‐world data are also used in health economic analyses. Cancer registry incidence data and outcomes data linked to Medicare claims were used to show rituximab's cost‐effectiveness for chronic lymphocytic leukemia and certain lymphomas in the United States …”

Section: Optimizing Cancer Medicine Researchmentioning

confidence: 99%

Enhancing global access to cancer medicines

Cortés

Peréz-García

Llombart-Cussac

et al. 2020

CA A Cancer J Clinicians

145

108

View full text Add to dashboard Cite

Globally, cancer is the second leading cause of death, with numbers greatly exceeding those for human immunodeficiency virus/acquired immunodeficiency syndrome, tuberculosis, and malaria combined. Limited access to timely diagnosis, to affordable, effective treatment, and to high‐quality care are just some of the factors that lead to disparities in cancer survival between countries and within countries. In this article, the authors consider various factors that prevent access to cancer medicines (particularly access to essential cancer medicines). Even if an essential cancer medicine is included on a national medicines list, cost might preclude its use, it might be prescribed or used inappropriately, weak infrastructure might prevent it being accessed by those who could benefit, or quality might not be guaranteed. Potential strategies to address the access problems are discussed, including universal health coverage for essential cancer medicines, fairer methods for pricing cancer medicines, reducing development costs, optimizing regulation, and improving reliability in the global supply chain. Optimizing schedules for cancer therapy could reduce not only costs, but also adverse events, and improve access. More and better biomarkers are required to target patients who are most likely to benefit from cancer medicines. The optimum use of cancer medicines depends on the effective delivery of several services allied to oncology (including laboratory, imaging, surgery, and radiotherapy). Investment is necessary in all aspects of cancer care, from these supportive services to technologies, and the training of health care workers and other staff.

show abstract

“…Three studies and two abstracts in FL met the eligibility criteria for final inclusion. One study assessed patients who received prior treatment [30], while the other four included only treatment-naïve patients [26,[31][32][33]. Treatment regimens, when reported, all incorporated the use of R in monotherapy or combination.…”

Section: Costs/resource Usementioning

confidence: 99%

“…The time horizon ranged from 1 year [30] to a lifetime [32,33]. Studies were conducted from the health care payer perspective, when reported [30][31][32]34]. Table 4 provides direct cost results, with direct drug and non-drug costs further depicted in electronic supplementary Table 5.…”

Section: Costs/resource Usementioning

confidence: 99%

Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews

Monga¹,

Garside

Gurung

et al. 2020

PharmacoEconomics Open

View full text Add to dashboard Cite

Background Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are types of indolent non-Hodgkin lymphoma (NHL) that develop in the B lymphocytes (also known as B cells).Objective The aim of this study was to conduct a comprehensive review of studies relating to cost effectiveness, costs and resource use, and health-related quality of life (HRQoL) in patients with FL or MZL. Methods Three separate systematic reviews were conducted to identify all published evidence on cost effectiveness, costs and resource use, and HRQoL between 2007 and March 2017 using the MEDLINE ® , MEDLINE in-process, E-pubs ahead of print (Ovid SP ® ), Embase (Ovid SP ® ), NHS EED, and EconLit databases. Select congress proceedings were also searched. Two systematic reviewers independently reviewed titles, abstracts, and full papers against eligibility criteria. Relevant data were extracted into bespoke data extraction templates (DETs) by a single systematic reviewer; these data were then validated for accuracy by a second reviewer against clean copies of the relevant publications. Results A total of 25 cost-effectiveness studies (24 in FL; 1 in FL and MZL) met the eligibility criteria. Markov models were the most utilised cost-effectiveness model. US FL studies reported an incremental cost-effectiveness ratio (ICER) of $28,565/QALY for first-line rituximab-cyclophosphamide, vincristine, and prednisone (R-CVP) versus CVP, and $43,000/ QALY for second-line obinutuzumab plus bendamustine (G + B) followed by G maintenance versus B. In the UK, ICERs were £1529-10,834/quality-adjusted life-year (QALY) for first-line rituximab + chemotherapy versus chemotherapy, £27,988/ QALY for second-line G + B + G-maintenance versus B, and £62,653/QALY for second-line idelalisib versus chemotherapy and/or rituximab. Five costs/resource use and four HRQoL studies were identified in FL, and none in MZL. US mean lifetime costs in first-line patients ranged from $108,000 (rituximab) to $130,300 (rituximab-cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone [CHOP]), and from £2185 (watch-and-wait) to £17,054 (chemotherapy) in the UK. In a multinational study, more rituximab-refractory patients receiving G + B + G-maintenance reported a meaningful improvement in total FACT-Lym scores compared with patients receiving B. In the UK, total FACT-Lym scores were meaningfully higher for newly diagnosed patients compared with patients with progression (136.04 vs. 109.7). Conclusions and RelevanceWe found a small body of evidence of quality of life, and potentially cost-effective treatment options for FL; however, no evidence was reported on MZL specifically. The significant data gaps in knowledge in these diseases demonstrate a marked need for further studies.

show abstract

Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data

Abstract: Supplemental Digital Content is available in the text.

Cited by 24 publications

References 29 publications

Treatment of primary membranous nephropathy: where are we now?

Treatment of primary membranous nephropathy: where are we now?

Enhancing global access to cancer medicines

Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews

Contact Info

Product

Resources

About